Overview

A Study of LY3209590 in Healthy Participants and Participants With Type 2 Diabetes

Status:
Completed
Trial end date:
2017-10-18
Target enrollment:
Participant gender:
Summary
This trial is conducted to evaluate the safety of a study drug given by injection under the skin to healthy participants and participants with type 2 diabetes. It will also investigate how the body processes the study drug and the effect of the study drug on blood sugar levels. Information about any side effects and tolerability will be documented. This study is approximately 30 days for each participant, not including screening. Screening is required within 28 days prior to the start of the study.
Phase:
Phase 1
Details
Lead Sponsor:
Eli Lilly and Company
Treatments:
Insulin
Insulin Glargine
Insulin, Globin Zinc